Arbutus Biopharma (ABUS) Equity Ratio (2010 - 2026)

Arbutus Biopharma has disclosed Equity Ratio across 17 years of filings, most recently posting 0.94 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.94, up 38.76% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (up 38.76% YoY), and the FY2025 annual result was 0.81, up 9.48% from the prior year.
• Equity Ratio came in at 0.94 for Q1 2026 at Arbutus Biopharma, up from 0.81 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.94 in Q1 2026 to a low of 0.68 in Q1 2025.
• The 5-year median for Equity Ratio is 0.75 (2023), against an average of 0.76.
• Across the five-year window, Equity Ratio slipped 15.49% in 2022 and soared 38.76% in 2026, its largest moves.
• Arbutus Biopharma's Equity Ratio stood at 0.7 in 2022, then grew by 4.84% to 0.73 in 2023, then gained by 0.69% to 0.74 in 2024, then rose by 9.48% to 0.81 in 2025, then climbed by 15.99% to 0.94 in 2026.
• The last three Equity Ratio figures came in at 0.94 (Q1 2026), 0.81 (Q4 2025), and 0.79 (Q3 2025), per Business Quant data.